These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 31261371

  • 1. Six-monthly palivizumab prophylaxis effectively reduced RSV-associated hospitalization rates of preterm infants in a subtropical area: a population-based cohort study.
    Lin YJ, Chung CH, Chi H, Lin CH.
    Pediatr Res; 2019 Nov; 86(5):628-634. PubMed ID: 31261371
    [Abstract] [Full Text] [Related]

  • 2. Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants.
    Forbes ML, Kumar VR, Yogev R, Wu X, Robbie GJ, Ambrose CS.
    Hum Vaccin Immunother; 2014 Nov; 10(10):2789-94. PubMed ID: 25483663
    [Abstract] [Full Text] [Related]

  • 3. Seasonal peaks and risk factors of respiratory syncytial virus infections related hospitalization of preterm infants in Taiwan.
    Chi H, Chung CH, Lin YJ, Lin CH.
    PLoS One; 2018 Nov; 13(5):e0197410. PubMed ID: 29746578
    [Abstract] [Full Text] [Related]

  • 4. Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29-34 wGA) infants without outpatient palivizumab administration.
    Packnett ER, Winer IH, Oladapo A, Wojdyla M.
    Hum Vaccin Immunother; 2023 Aug; 19(2):2252289. PubMed ID: 37828711
    [Abstract] [Full Text] [Related]

  • 5. Prolonged seasonality of respiratory syncytial virus infection among preterm infants in a subtropical climate.
    Hsu CH, Lin CY, Chi H, Chang JH, Hung HY, Kao HA, Peng CC, Jim WT.
    PLoS One; 2014 Aug; 9(10):e110166. PubMed ID: 25333346
    [Abstract] [Full Text] [Related]

  • 6. RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020.
    Packnett ER, Winer IH, Larkin H, Oladapo A, Gonzales T, Wojdyla M, Goldstein M, Smith VC.
    Hum Vaccin Immunother; 2022 Nov 30; 18(6):2140533. PubMed ID: 36412253
    [Abstract] [Full Text] [Related]

  • 7. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.
    Sanchez-Luna M, Burgos-Pol R, Oyagüez I, Figueras-Aloy J, Sánchez-Solís M, Martinón-Torres F, Carbonell-Estrany X.
    BMC Infect Dis; 2017 Oct 17; 17(1):687. PubMed ID: 29041909
    [Abstract] [Full Text] [Related]

  • 8. Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy: An International, Prospective Cohort Study.
    Manzoni P, Paes B, Lanctôt KL, Dall'Agnola A, Mitchell I, Calabrese S, Maule M, Girardi E, Harimoto T, Li A.
    Pediatr Infect Dis J; 2017 Jan 17; 36(1):2-8. PubMed ID: 27649365
    [Abstract] [Full Text] [Related]

  • 9. Effect of Prophylactic Palivizumab on Admission Due to Respiratory Syncytial Virus Infection in Former Very Low Birth Weight Infants with Bronchopulmonary Dysplasia.
    Han YM, Seo HJ, Choi SH, Jung YJ, Ahn SY, Yoo HS, Sung SI, Shim JW, Lee YK, Ko SY, Shin SM, Hwang JH, Lee JH, Choi BM, Kim ES, Jeon JH, Kim SS, Chang YS, Park WS.
    J Korean Med Sci; 2015 Jul 17; 30(7):924-31. PubMed ID: 26130956
    [Abstract] [Full Text] [Related]

  • 10. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.
    Oncel MY, Mutlu B, Kavurt S, Baş AY, Demirel N, Akyol M, Erdeve O, Dilmen U.
    Turk J Pediatr; 2012 Jul 17; 54(4):344-51. PubMed ID: 23692714
    [Abstract] [Full Text] [Related]

  • 11. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR.
    Pediatr Infect Dis J; 2003 Feb 17; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis.
    Cetinkaya M, Oral TK, Karatekin S, Cebeci B, Babayigit A, Yesil Y.
    Eur J Clin Microbiol Infect Dis; 2017 Sep 17; 36(9):1629-1634. PubMed ID: 28391538
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A novel six consecutive monthly doses of palivizumab prophylaxis protocol for the prevention of respiratory syncytial virus infection in high-risk preterm infants in Taiwan.
    Chi H, Hsu CH, Chang JH, Chiu NC, Hung HY, Kao HA, Weng LC, Huang FY, Chiu YY, Chang LY, Huang LM.
    PLoS One; 2014 Sep 17; 9(6):e100981. PubMed ID: 24971565
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
    Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J, IRIS Study Group.
    Pediatr Infect Dis J; 2003 Sep 17; 22(9):823-7. PubMed ID: 14506376
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era.
    Resch B, Egger B, Kurath-Koller S, Urlesberger B.
    Int J Infect Dis; 2017 Apr 17; 57():50-53. PubMed ID: 28163166
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.